e-learning
resources
Berlin 2008
Monday, 06.10.2008
Problems in managing pulmonary and extrapulmonary tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
S. Y. Low, P. Eng (Singapore, Singapore)
Source:
Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
Session:
Problems in managing pulmonary and extrapulmonary tuberculosis
Session type:
Thematic Poster Session
Number:
2375
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Y. Low, P. Eng (Singapore, Singapore). Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?. Eur Respir J 2008; 32: Suppl. 52, 2375
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen
Source: Eur Respir J 2002; 20: Suppl. 38, 359s
Year: 2002
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis
Source: International Congress 2018 – Drug-resistant tuberculosis
Year: 2018
Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis
Source: Eur Respir J 2007; 30: Suppl. 51, 197s
Year: 2007
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003
Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB
Source: Eur Respir J 2006; 28: Suppl. 50, 8s
Year: 2006
Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART
Source: Breathe 2008; 5: 274
Year: 2009
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent
Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities
Year: 2019
Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs
Source: Eur Respir J 2002; 20: Suppl. 38, 614s
Year: 2002
Efficiency of intravenous treatment with levofloxacin in patients with MDR pulmonary tuberculosis in the intensive phase of chemotherapy
Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis
Year: 2021
Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem
Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis
Year: 2007
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019
Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019
Year: 2019
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?
Source: Eur Respir J 2009; 34: 1492-1494
Year: 2009
Effectiveness of the intensive phase of chemotherapy in pulmonary TB patients with primary drug resistance
Source: Eur Respir J 2006; 28: Suppl. 50, 290s
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept